Octapharma USA, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$6.6Mgeneral payments (2019-2025)
$690Kresearch payments (2019-2025)
10,781clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Fibryga $2.4M associated (2023-2025)
- Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) $1.0M associated (2023-2025)
- Octagam Immune Globulin (Human) $450K associated (2023-2025)
- Cutaquig $408K associated (2023-2025)
- Panzyga $373K associated (2023-2025)
- Nuwiq $239K associated (2023-2025)
- Fibryga & Balfaxar $217K associated (2023-2025)
- Balfaxar $107K associated (2023-2025)
- Ivig $29K associated (2023-2025)
- Octaplas $18K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Adit Ginde | Aurora, CO | Emergency Medicine | $1,700,000.00 |
| Jill Johnsen | Seattle, WA | Hematology & Oncology | $779,053.00 |
| Isaac Melamed | Centennial, CO | $496,378.83 | |
| Mazen Dimachkie | Houston, TX | Neurology (Psychiatry & Neurology) | $133,963.78 |
| Robert Sidonio | Atlanta, GA | Pediatric Hematology-Oncology | $124,334.28 |
| Lawrence Steinman | Palo Alto, CA | Neurology (Psychiatry & Neurology) | $114,105.00 |
| Daniel Katz | New York, NY | Anesthesiology | $103,446.04 |
| Tjorvi Perry | Minneapolis, MN | Anesthesiology | $77,421.34 |
| Grace Lim | Mountain View, CA | Pediatrics | $76,215.00 |
| Rohit Aggarwal | Pittsburgh, PA | Rheumatology | $69,593.69 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.